It is therefore interesting that early‐phase clinical trials involving vaccines against T in patients with lung cancer and chordoma are showing some evidence of clinical activity 79, 80, 81, and it would be of interest to know whether p‐EGFR is suppressed in the clinical samples from these patients. The gene discussed is EGFR; the disease is lung cancer.